TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
RxSight ( (RXST) ) has shared an update.
On July 31, 2025, RxSight, Inc. expanded its board of directors by appointing Raymond W. Cohen, an experienced medical technology executive, as a Class I director. Cohen’s extensive industry expertise is expected to help RxSight strengthen its position in the premium intraocular lens market and accelerate growth in revenue and profits. His previous leadership roles, including the successful sale of Axonics, Inc. and SoniVie Ltd. to Boston Scientific, highlight his capability to drive company growth and expansion.
The most recent analyst rating on (RXST) stock is a Buy with a $59.00 price target. To see the full list of analyst forecasts on RxSight stock, see the RXST Stock Forecast page.
Spark’s Take on RXST Stock
According to Spark, TipRanks’ AI Analyst, RXST is a Neutral.
The primary factors affecting RxSight’s score are its inadequate profitability and negative cash flow, which weigh heavily despite strong revenue growth and a stable balance sheet. Technical indicators suggest bearish momentum, and the revised revenue guidance in the earnings call further pressures the stock’s outlook. The valuation remains unattractive with a negative P/E ratio.
To see Spark’s full report on RXST stock, click here.
More about RxSight
RxSight, Inc. is an ophthalmic medical device company focused on providing high-quality customized vision solutions for patients after cataract surgery. Their primary product, the RxSight® Light Adjustable Lens system, is the only commercially available intraocular lens technology that can be adjusted post-surgery to deliver tailored vision outcomes.
Average Trading Volume: 1,287,156
Technical Sentiment Signal: Sell
Current Market Cap: $317M
For an in-depth examination of RXST stock, go to TipRanks’ Overview page.